Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102689 | 0.90 | IRAK4 (0.44) | CCNT1CDK1CCNB1CDK9CDK7 | |
| SCHEMBL30459760 | 0.84 | CYP11B1 (0.43) | CYP11B1CYP11B2CCNT1CDK1CCNB1 | |
| SCHEMBL17683145 | 0.84 | CYP11B1 (0.43) | CYP11B1CYP11B2CCNT1CDK1CCNB1 | |
| SCHEMBL3823223 | 0.83 | CDK1 (0.53) | CYP11B1CYP11B2CCNT1CDK1CCNB1 | |
| SCHEMBL30459679 | 0.82 | NR3C1 (0.42) | CYP11B1CYP11B2CCNT1CDK1CCNB1 | |
| SCHEMBL17683115 | 0.82 | LRRK2 (0.40) | CCNT1CDK1CCNB1CDK9CDK7 | |
| SCHEMBL17683288 | 0.82 | NR3C1 (0.42) | CYP11B1CYP11B2CCNT1CDK1CCNB1 | |
| SCHEMBL17683358 | 0.79 | CYP11B1 (0.43) | CYP11B1CYP11B2ROCK1NR3C1KDR | |
| SCHEMBL5096332 | 0.76 | ROCK1 (0.42) | CYP11B1CYP11B2CCNT1CDK1CCNB1 | |
| SCHEMBL7022991 | 0.74 | LCK (0.52) | ROCK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | CYP11B1 663/4885CYP11B2 967/4885CCNT1 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.